Candidiasis, Invasive
-
Subject Areas on Research
- A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis.
- Advances in the treatment of invasive neonatal candidiasis.
- Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis.
- Antifungal therapy and outcomes in infants with invasive Candida infections.
- CX3CR1-dependent renal macrophage survival promotes Candida control and host survival.
- Changes in the incidence of candidiasis in neonatal intensive care units.
- Clinical characteristics and response to prophylactic fluconazole of preterm VLBW neonates with baseline and acquired fungal colonisation in NICU: data from a multicentre RCT.
- Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.
- Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options.
- Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study.
- Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.
- Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants.
- Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial.
- Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis.
- Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.
- Fluconazole Prophylaxis for the Prevention of Candidiasis in Premature Infants: A Meta-analysis Using Patient-level Data.
- Fluconazole pharmacokinetics and safety in premature infants.
- Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.
- Fluconazole prophylaxis for prevention of invasive candidiasis in infants.
- Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.
- Neonatal fungal infections: when to treat?
- Neonatal invasive candidiasis: updates on clinical management and prevention.
- Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population.
- Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis.
- Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.
- Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates.
- Risk factors for invasive candidiasis in infants >1500 g birth weight.
- Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.
- Safety of micafungin in infants: insights into optimal dosing.
- The epidemiology and diagnosis of invasive candidiasis among premature infants.
- The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).
- Treatment and prophylaxis of invasive candidiasis.
- β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study.
-
Keywords of People
- Cohen-Wolkowiez, Michael, Kiser-Arena Distinguished Professor, Pediatrics, Infectious Diseases